Oncology NDAs Based On Single-Arm Studies Run Risk Of FDA Refusal To File
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Oncology drug sponsors who seek FDA accelerated approval based upon single-arm studies run the risk of a “refuse-to-file” letter, a new analysis suggests.